stoxline Quote Chart Rank Option Currency Glossary
Oragenics, Inc. (OGEN)
1.23  0 (0%)    04-12 15:59
Open: 1.27
High: 1.27
Volume: 19,785
Pre. Close: 1.23
Low: 1.18
Market Cap: 6(M)
Technical analysis
2024-04-12 4:51:16 PM
Short term     
Mid term     
Targets 6-month :  1.6 1-year :  1.76
Resists First :  1.37 Second :  1.5
Pivot price 1.33
Supports First :  1.15 Second :  0.96
MAs MA(5) :  1.25 MA(20) :  1.35
MA(100) :  3.42 MA(250) :  3.33
MACD MACD :  -0.3 Signal :  -0.3
%K %D K(14,3) :  18.1 D(3) :  24.2
RSI RSI(14): 33.5
52-week High :  7.73 Low :  1.15
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ OGEN ] has closed above bottom band by 26.5%. Bollinger Bands are 78.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.27 - 1.28 1.28 - 1.28
Low: 1.16 - 1.17 1.17 - 1.18
Close: 1.22 - 1.23 1.23 - 1.24
Company Description

Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

Headline News

Mon, 08 Apr 2024
Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at - Defense World

Mon, 01 Apr 2024
Oragenics, Inc. Files 10K and Provides Company Update - Business Wire

Fri, 01 Mar 2024
Oragenics Announces Closing of Public Offering - Business Wire

Fri, 01 Mar 2024
Oragenics Inc Enhances Financial Standing with Equity Sale - - TipRanks

Wed, 28 Feb 2024
Oragenics Inc Announces Proposed Public Stock Offering - - TipRanks

Wed, 28 Feb 2024
Why Is Oragenics (OGEN) Stock Down 45% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 3 (M)
Held by Insiders 2.03e+006 (%)
Held by Institutions 20.7 (%)
Shares Short 52 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.037e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -28 %
Return on Assets (ttm) 53.1 %
Return on Equity (ttm) -52.2 %
Qtrly Rev. Growth 37650 %
Gross Profit (p.s.) -182.61
Sales Per Share -186.42
EBITDA (p.s.) -1.988e+007
Qtrly Earnings Growth -4.6 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -9 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.32
Stock Dividends
Dividend 0
Forward Dividend 40610
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android